Rubicon Research LimitedRUBICONCorporate

Healthcare Drug Manufacturers - General Latest results: Jun 2026 6 quarters of data

₹1,508.60

MCap ₹24,906 Cr · P/E 86.3

Rubicon Research Limited — Stock analysis & AI research Rubicon Research Limited — Multibagger AI analysis Rubicon Research Limited — Seasonality — best & worst months Rubicon Research Limited — Technical indicators & charts Rubicon Research Limited — Technical setup — score, trend, support & resistance Rubicon Research Limited — Live exchange announcements

📋 Stocks With Strong Quarterly Results 📋 Small Cap Stocks List ⚖️ vs Acutaas Chemicals ⚖️ vs Cohance Lifesciences 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹534 Cr

Sales · Jun 2026

+51.8% YoY

₹129 Cr

Operating Profit · Jun 2026

+63.4% YoY

24.2%

OPM % · Jun 2026

+8.0% YoY

₹85 Cr

Net Profit · Jun 2026

+97.2% YoY

₹5.13

EPS · Jun 2026

+82.6% YoY

📝 Rubicon Research Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Rubicon Research Limited reported revenue of ₹534 crore for the quarter ended June 2026 (Q1 FY27), up 51.8% from ₹352 crore in the same quarter last year, and up 4.0% sequentially over the March 2026 quarter.

Net profit rose 97.2% year-on-year to ₹85 crore, from ₹43 crore. Earnings per share (EPS) came in at ₹5.13.

Operating profit stood at ₹129 crore — an operating margin (OPM) of 24.2%, compared with 22.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Rubicon Research Limited posted revenue of ₹1,754 crore, with a net profit of ₹247 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,936 crore with a net profit of ₹288 crore.

Valuation snapshot

At the current price of ₹1,508.60, RUBICON has a market capitalisation of ₹24,906 crore and a trailing P/E of about 86.3.

Within the Drug Manufacturers - General industry, it is the 2nd-largest of the 5 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 59.76%, foreign institutional investors (FIIs) 7.52%, domestic institutional investors (DIIs) 9.43%, public shareholders 23.30% of Rubicon Research Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹24,906 Cr

Current Price ?

₹1,508.6

P/E ?

86.35above ind

Industry P/E ?

62.30

P/B ?

N/A

P/S ?

12.87

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

1.2%

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

₹1,936 Cr

OPM ?

23.3%

Profit after tax (TTM) ?

₹288 Cr

EPS (TTM) ?

₹17.47

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹534 Cr

PAT — latest qtr ?

₹85 Cr

YoY qtr sales growth ?

51.8%

YoY qtr profit growth ?

97.2%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

N/A

Debt to Equity ?

N/A

Interest Coverage ?

8.4

Current Ratio ?

N/A

Ownership

Promoter holding ?

59.76%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

4.8%

Return 6 months ?

67.8%

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	358	352	412	476	514	534	+51.8%	+4.0%
Operating Profit	72	79	94	108	119	129	+63.4%	+8.5%
Other Income	0	1	1	4	3	6	+468.3%	+89.4%
Interest	12	11	11	10	10	9	-15.6%	-7.1%
Depreciation	10	10	12	12	12	15	+51.4%	+26.2%
Profit Before Tax	51	60	72	91	99	110	+84.0%	+11.5%
Net Profit	36	43	54	73	77	85	+97.2%	+10.1%
EPS	2.35	2.81	3.49	4.46	4.65	5.13	+82.6%	+10.3%
OPM %	20.1%	22.4%	22.9%	22.7%	23.2%	24.2%	+8.0%	+4.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	Prev FY	FY26	TTM	YoY %
Sales	—	₹1,754 Cr	₹1,936 Cr	—
Operating Profit	—	₹400 Cr	₹451 Cr	—
OPM %	—	22.84%	23.27%	—
NPM %	—	14.07%	14.90%	—
Other Income	—	₹8 Cr	₹13 Cr	—
Depreciation	—	₹45 Cr	₹51 Cr	—
Interest	—	₹42 Cr	₹40 Cr	—
EBIT	—	₹355 Cr	₹400 Cr	—
PBT	—	₹321 Cr	₹372 Cr	—
Tax	—	₹226 Cr	₹252 Cr	—
Net Profit	—	₹247 Cr	₹288 Cr	—
EPS	—	₹15.41	₹17.73	—
Material Cost	—	₹369 Cr	₹545 Cr	—
Employee Cost	—	₹130 Cr	₹215 Cr	—
Extraordinary Items	—	—	—	—

👥 Shareholding (latest 1 periods)

Metric	Jun 2026	% Chg
Promoters	59.76%	—
FIIs	7.52%	—
DIIs	9.43%	—
Public	23.30%	—
No. of Shareholders	43,254	—

⚖️ Peer comparison

Industry: Drug Manufacturers - General · 5 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	GLAXO GlaxoSmithKline Pharmaceuticals	₹2,818.90	47,754	44.7	3,955	1,068	40.8%	27.0%	1.9%	11.6%	16.6%	15.7%
2	RUBICON RUBICON RESEARCH	₹1,839.40	30,367	103.7	1,936	288	23.3%	14.9%	—	—	51.8%	97.2%
3	PFIZER Pfizer	₹4,055.00	18,551	25.2	2,569	735	36.7%	28.6%	10.4%	-5.8%	8.3%	6.2%
4	SAIPARENT Sai Parenterals	₹498.00	2,200	—	—	—	—	—	—	—	435.1%	458.0%
5	SYMBIOTEC Symbiotec Pharmalab	₹1,107.00	—	—	—	—	—	—	—	—	7.5%	-53.1%

❓ Frequently asked questions

What was Rubicon Research Limited's revenue in Q1 FY27?

What was Rubicon Research Limited's net profit in Q1 FY27?